CISEN(SH:603367)2023-03-30 16:00Financial Performance - The company achieved an operating revenue of RMB 4.066 billion in 2022, representing a year-on-year increase of 7.49%[24]. - The net profit attributable to shareholders was RMB 350.07 million, an increase of 4.77% compared to the previous year[24]. - The net profit after deducting non-recurring gains and losses was RMB 331.44 million, reflecting a growth of 10.32% year-on-year[24]. - The cash flow from operating activities amounted to RMB 258.35 million, up by 10.59% from the previous year[24]. - The total assets of the company reached RMB 6.815 billion at the end of 2022, an increase of 7.09% compared to the end of 2021[24]. - The basic earnings per share were RMB 0.77, a 4.05% increase from the previous year[25]. - The weighted average return on equity was 6.76%, slightly up from 6.73% in 2021[25]. - The company reported a total profit of RMB 366 million for the year, which is an 8.94% increase year-on-year[35]. - The company reported a significant increase in financial income, contributing to a reduction in financial expenses by 206.86%[58]. - The total revenue for the year 2022 reached approximately ¥4.05 billion, with a year-on-year increase of 7.32%[61]. Dividend Policy - The company plans to distribute a cash dividend of 3.35 RMB per 10 shares, totaling approximately 151.68 million RMB based on 452,775,129 shares[5]. - The total cash dividend amount distributed was approximately ¥151.68 million, which represents 43.33% of the net profit attributable to ordinary shareholders[164]. - The company implemented a cash dividend policy, distributing a cash dividend of 3.00 RMB per 10 shares, amounting to a total of 135,850,238.70 RMB, which represents 40.66% of the net profit attributable to shareholders[155][156]. - The company’s profit distribution policy emphasizes stable and continuous cash dividends, with a focus on maintaining a balance between shareholder returns and sustainable development[157][158]. Research and Development - The company is committed to enhancing its product structure through internal R&D and collaborations with external research institutions, focusing on high-margin products[36]. - The company has engaged in research collaborations with multiple prestigious institutions, facilitating new product development[53]. - R&D investment accounted for over 8% of operating revenue, supporting the company's sustainable development[56]. - The company invested CNY 335 million in R&D in 2022, maintaining an R&D expenditure ratio of over 8% of sales revenue[92]. - There are over 100 ongoing R&D projects focusing on complex injectables, controlled-release oral solid formulations, and other therapeutic areas[93]. - The company is actively seeking collaborations for R&D projects under the new MAH policy to enhance its product pipeline[92]. - The company has completed preclinical research for a new drug targeting autoimmune inflammation and an antiviral drug, both of which have applied for Pre-IND[94]. - The company has established R&D subsidiaries in India, Tianjin, and Jinan to enhance innovation and resource sharing[92]. Market Expansion and Sales Strategy - The company continues to focus on market demand and has been enhancing its sales management system and service tools[35]. - In 2022, the company established a nationwide sales network for new and generic drugs, focusing on OTC drugs, special medical foods, and traditional Chinese medicine, creating three new growth points[36]. - The company expanded its sales team and implemented a four-level training program to enhance the quality of its sales personnel, aiming for professional and precise market services[36]. - The sales model includes both direct sales to hospitals and retail pharmacies, as well as distribution through pharmaceutical companies[51]. - The company plans to focus on expanding its market presence and enhancing its product development strategies in the upcoming year[61]. - The company is investing $200 million in research and development for new technologies over the next two years[85]. - Market expansion efforts include entering two new countries, which are expected to generate an additional $50 million in revenue[86]. Corporate Governance - The company has implemented a governance structure that complies with relevant laws and regulations, ensuring effective internal control and protection of shareholder rights[121]. - The board of directors has established four specialized committees to provide scientific and professional opinions for decision-making[122]. - The company has maintained independence from its controlling shareholder, ensuring no adverse impact on its operations[123]. - The company has adhered to information disclosure regulations, ensuring transparency and equal access to information for all shareholders[124]. - The company held multiple shareholder meetings, ensuring compliance with legal requirements and timely disclosure of resolutions[126]. Environmental Management - The company has established an environmental management department to adapt to stringent environmental regulations and improve operational management capabilities[119]. - The company has received various environmental impact approvals for its projects, demonstrating compliance with regulatory requirements[178]. - The company has implemented an environmental self-monitoring plan, with third-party testing confirming that all pollutant indicators meet discharge standards[183]. - The company has committed to continuous improvement in waste management, with all hazardous waste being handled by authorized environmental firms[190]. - The company has installed activated carbon treatment equipment for exhaust emissions, ensuring compliance with environmental standards[176]. Risk Management - The company faces risks related to macroeconomic conditions and policy changes that could impact its operations and profitability[118]. - Fluctuations in raw material prices pose a significant risk to the company's production costs and profit margins, necessitating proactive procurement strategies[118]. - The company faces risks from intensified industry competition, particularly in the generic and innovative drug sectors, and will focus on maintaining competitive advantages[119]. Employee Development - The company conducted over 1,000 training sessions in 2022, with an average of 50 hours of training per employee, significantly enhancing the overall quality of its workforce[153]. - The company has established a comprehensive training management system, focusing on various functional modules including R&D, sales, quality, production, and safety[153]. - The total number of employees in the parent company is 2,905, and the total number of employees in major subsidiaries is 508, resulting in a combined total of 3,413 employees[150].